DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Extrapulmonary Neuroendocrine Cancer

Interventions

DRUG: Obrixtamig
DRUG: Carboplatin
DRUG: Etoposide
DEVICE: Ventana DLL3 RxDx assay

Sponsor

Boehringer Ingelheim